FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4237288519> ?p ?o ?g. }

• W4237288519 endingPage "383" @default.
• W4237288519 startingPage "369" @default.
• W4237288519 abstract "It has been widely accepted for a number of years that chrysotherapy is a valuable therapeutic agent in the treatment of progressive rheumatoid disease. This therapeutic benefit has, to some extent, been offset by the potential toxicity associated with gold compounds. The development of a gold compound with a greater therapeutic to toxicity ratio would be of considerable interest and benefit, to both patients and physicians. Initial studies with auranofin suggested that this compound was a reliably absorbed agent and that its use would avoid regular gold thiol injections. Its initial therapeutic profile was considered to be similar to that of injectable gold compounds, but with a significantly greater safety margin. The further information that has accrued from the clinical studies reported so far would tend to support these early suggestions in that auranofin has compared very favourably with gold thiols and other disease-remittive agents and that the prevalence of side effects requiring withdrawal of therapy has been approximately 25–30 per cent less. In addition, the reasons for withdrawal have often been less potentially serious side effects, notably nephrotoxicity and haematological reactions. In a review of over 3000 patients treated with auranofin, compared to 465 patients treated with injectable gold, the frequency of withdrawal from studies due to inefficacy of auranofin was approximately two to three times higher than with the gold thiols. It would appear, therefore, that in those patients continuing on therapy, auranofin is similar to injectable gold, but that a higher proportion of patients will fail to get a response within three to six months to the therapy. This potential lack of therapeutic effect is offset by the increased safety margin. In time, it is possible that auranofin will be accepted for earlier treatment in the course of rheumatoid disease than perhaps would normally have been considered. The in vivo and in vitro studies of auranofin on its mechanism of action are of considerable interest. They provide theoretical and valuable information on the mechanism of action of gold compounds and the cellular functions and interactions which may be involved in the pathogenesis of rheumatoid disease. It is interesting to note that auranofin appears to be more potent and have different effects than gold thiols, despite the fact that in terms of clinical therapeutic profile the compounds are similar. When the results of ongoing studies are finally analysed, auranofin may provide an alternative therapy to the currently available injectable gold compounds, and may well prove to be a useful addition to the therapeutic armamentarium in the treatment of patients with progressive rheumatoid arthritis." @default.
• W4237288519 created "2022-05-12" @default.
• W4237288519 creator A5064680897 @default.
• W4237288519 date "1984-08-01" @default.
• W4237288519 modified "2023-10-18" @default.
• W4237288519 title "Auranofin" @default.
• W4237288519 cites W1039422329 @default.
• W4237288519 cites W1970443691 @default.
• W4237288519 cites W1988883152 @default.
• W4237288519 cites W2006131961 @default.
• W4237288519 cites W2023193670 @default.
• W4237288519 cites W2089325545 @default.
• W4237288519 cites W2089582175 @default.
• W4237288519 cites W2110658657 @default.
• W4237288519 cites W2119445799 @default.
• W4237288519 cites W2172011800 @default.
• W4237288519 doi "https://doi.org/10.1016/s0307-742x(21)00508-7" @default.
• W4237288519 hasPublicationYear "1984" @default.
• W4237288519 type Work @default.
• W4237288519 citedByCount "11" @default.
• W4237288519 countsByYear W42372885192014 @default.
• W4237288519 countsByYear W42372885192018 @default.
• W4237288519 countsByYear W42372885192019 @default.
• W4237288519 crossrefType "journal-article" @default.
• W4237288519 hasAuthorship W4237288519A5064680897 @default.
• W4237288519 hasConcept C126189478 @default.
• W4237288519 hasConcept C126322002 @default.
• W4237288519 hasConcept C141071460 @default.
• W4237288519 hasConcept C2776243873 @default.
• W4237288519 hasConcept C2777575956 @default.
• W4237288519 hasConcept C2780570811 @default.
• W4237288519 hasConcept C29730261 @default.
• W4237288519 hasConcept C40993552 @default.
• W4237288519 hasConcept C71924100 @default.
• W4237288519 hasConcept C98274493 @default.
• W4237288519 hasConceptScore W4237288519C126189478 @default.
• W4237288519 hasConceptScore W4237288519C126322002 @default.
• W4237288519 hasConceptScore W4237288519C141071460 @default.
• W4237288519 hasConceptScore W4237288519C2776243873 @default.
• W4237288519 hasConceptScore W4237288519C2777575956 @default.
• W4237288519 hasConceptScore W4237288519C2780570811 @default.
• W4237288519 hasConceptScore W4237288519C29730261 @default.
• W4237288519 hasConceptScore W4237288519C40993552 @default.
• W4237288519 hasConceptScore W4237288519C71924100 @default.
• W4237288519 hasConceptScore W4237288519C98274493 @default.
• W4237288519 hasIssue "2" @default.
• W4237288519 hasLocation W42372885191 @default.
• W4237288519 hasOpenAccess W4237288519 @default.
• W4237288519 hasPrimaryLocation W42372885191 @default.
• W4237288519 hasRelatedWork W1994191513 @default.
• W4237288519 hasRelatedWork W1994790143 @default.
• W4237288519 hasRelatedWork W2024499960 @default.
• W4237288519 hasRelatedWork W2069603964 @default.
• W4237288519 hasRelatedWork W2120441278 @default.
• W4237288519 hasRelatedWork W2404655093 @default.
• W4237288519 hasRelatedWork W2410103609 @default.
• W4237288519 hasRelatedWork W2767706375 @default.
• W4237288519 hasRelatedWork W3025884475 @default.
• W4237288519 hasRelatedWork W970082845 @default.
• W4237288519 hasVolume "10" @default.
• W4237288519 isParatext "false" @default.
• W4237288519 isRetracted "false" @default.
• W4237288519 workType "article" @default.